Patents Assigned to Proximagen Limited
-
Patent number: 9035066Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: October 25, 2013Date of Patent: May 19, 2015Assignee: Proximagen LimitedInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20140357623Abstract: 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine; 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine; 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboType: ApplicationFiled: September 14, 2011Publication date: December 4, 2014Applicant: PROXIMAGEN LIMITEDInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Publication number: 20140329826Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: ApplicationFiled: May 9, 2014Publication date: November 6, 2014Applicant: Proximagen LimitedInventors: Tom Fleck, Magnus Cernerud, Helena Lundstrom, Claes Lofstrom, Margit Pelcman, Alexander Paptchikhine, Emma Nylen, Alf Nygren
-
Publication number: 20140275063Abstract: Compounds of formula (I) are inhibitors of Semicarbazide-sensitive amine oxidase R1—X—R2??(I) wherein R1, X and R2 are as defined in the claims.Type: ApplicationFiled: September 13, 2012Publication date: September 18, 2014Applicant: PROXIMAGEN LIMITEDInventors: Allison Carley, Iain Simpson
-
Publication number: 20140275040Abstract: The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Proximagen LimitedInventors: Max Espensen, Lee Patient, David Evans, Edward Savory, Iain Simpson
-
Publication number: 20140275068Abstract: The present invention provides neuronal gap junction blocking compounds according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein the integers Q, R2, A, R1, Z1, Z2, and Z3 are as defined in claim 1. The compounds are useful for the treatment or prevention of a range of conditions including, e.g., migraine, epilepsy, non-epileptic seizures, brain injury, and cardiovascular disease.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Proximagen LimitedInventors: Edward Savory, Daniel Hill, Oldrich Kocian
-
Patent number: 8835439Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: GrantFiled: February 15, 2013Date of Patent: September 16, 2014Assignee: Proximagen LimitedInventors: Tom Fleck, Magnus Cernerud, Helena Lundstrom, Claes Lofstrom, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
-
Patent number: 8796283Abstract: This invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 14, 2010Date of Patent: August 5, 2014Assignee: Proximagen LimitedInventors: Kevin Dinnell, Andrew Lightfoot, Gillian Elizabeth Lunniss
-
Publication number: 20140121219Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: October 25, 2013Publication date: May 1, 2014Applicant: Proximagen LimitedInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20130310380Abstract: Compounds are disclosed which modulate the ?7 nicotinic acetyl choline receptor (nAChR), having the formula (I) wherein the variables are as specified in the description and claims.Type: ApplicationFiled: October 26, 2011Publication date: November 21, 2013Applicant: Proximagen LimitedInventors: David Dean, Andrew Lightfoot, Susan Roomans
-
Publication number: 20130289020Abstract: Disclosed are compounds that are antagonists of the CXCR4 receptor.Type: ApplicationFiled: October 13, 2011Publication date: October 31, 2013Applicant: Proximagen LimitedInventors: Edward Daniel Savory, Allson Stewart, Allison Cartey, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
-
Publication number: 20130252951Abstract: The compounds of formula (I) are antagonists of the CCR2 receptor Wherein R1-7 and A are as defined in the claims.Type: ApplicationFiled: September 26, 2011Publication date: September 26, 2013Applicant: Proximagen LimitedInventors: Joe William Boyd, Paul Meo, Michael Higginbottom, Iain Simpson, David Mountford, Edward Daniel Savory
-
Publication number: 20130102587Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.Type: ApplicationFiled: March 14, 2011Publication date: April 25, 2013Applicant: PROXIMAGEN LIMITEDInventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister
-
Patent number: 8377941Abstract: The present invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of List A or a salt thereof, which may be represented, but is not limited to the compound N-[(2-Trifluoromethyl-1H-indol-5-yl)methyl]-2-(trifluoromethyl)-5-pyrimidinecarboxamide.Type: GrantFiled: April 16, 2009Date of Patent: February 19, 2013Assignee: Proximagen LimitedInventors: Kevin Dinnell, Andrew P Lightfoot, Howard Robert Marshall
-
Publication number: 20120302583Abstract: The present invention relates to a method for the treatment or prevention of inflammation, an inflammatory disease, an immune or an autoimmune disorder, which comprises administering to a mammal in need of such treatment an effective amount of a compound compound of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity.Type: ApplicationFiled: August 6, 2012Publication date: November 29, 2012Applicant: PROXIMAGEN LIMITEDInventors: Edward Daniel Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20120283273Abstract: This invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 14, 2010Publication date: November 8, 2012Applicant: PROXIMAGEN LIMITEDInventors: Kevin Dinnell, Andrew Lightfoot, Gillian Elizabeth Lunniss
-
Patent number: 8283365Abstract: This invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a salt thereofType: GrantFiled: April 16, 2009Date of Patent: October 9, 2012Assignee: Proximagen LimitedInventors: Kevin Dinnell, Andrew P Lightfoot, Howard Robert Marshall
-
Patent number: 8138333Abstract: The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: GrantFiled: March 13, 2008Date of Patent: March 20, 2012Assignee: Proximagen LimitedInventors: Johan Angbrant, Peter Brandt, Rune Ringom, Bengt Lindqvist
-
Publication number: 20110207746Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: September 16, 2009Publication date: August 25, 2011Applicant: PROXIMAGEN LIMITEDInventors: Edward Daniel Savory, Michael Higginbottom, Kathryn Oliver, VietAnh Anne Horgan
-
Publication number: 20110195992Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as such as inflammatory diseases and immune disorders.Type: ApplicationFiled: September 16, 2009Publication date: August 11, 2011Applicant: PROXIMAGEN LIMITEDInventors: Edward Savory, Iain Simpson